Improved GRFS after posttransplant cyclophosphamide-based vs ATG-based HLA-mismatched unrelated donor transplant
暂无分享,去创建一个
M. Perales | S. Devlin | L. Lekakis | K. Komanduri | Trent P. Wang | A. Beitinjaneh | C. Sauter | Samantha Brown | B. Shaffer | D. Ponce | D. Pereira | M. Goodman | A. M. Jimenez Jimenez | Stephanie Chinapen | A. J. Jimenez Jimenez | T. Wang | Antonio M. Jimenez Jimenez
[1] G. Papanicolaou,et al. American Society for Transplantation and Cellular Therapy Series: #3-Prevention of Cytomegalovirus Infection and Disease After Hematopoietic Cell Transplantation. , 2021, Transplantation and cellular therapy.
[2] G. Marcucci,et al. Posttransplant cyclophosphamide as GVHD prophylaxis for peripheral blood stem cell HLA-mismatched unrelated donor transplant. , 2021, Blood advances.
[3] M. Norkin,et al. National Marrow Donor Program–Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] M. Norkin,et al. Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] C. Zwaan,et al. Prospective Open-Label Phase II Trial of Individualized Anti-Thymocyte Globulin for Improved T-Cell Reconstitution after Pediatric Allogeneic Hematopoietic Cell Transplantation: The Parachute-Study , 2020 .
[6] R. Bouabdallah,et al. Posttransplantation cyclophosphamide vs. antithymocyte globulin as GVHD prophylaxis for mismatched unrelated hematopoietic stem cell transplantation , 2019, Bone Marrow Transplantation.
[7] M. Perales,et al. Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP/CIBMTR , 2019, Blood.
[8] J. Wagner,et al. Alternative donor transplantation for acute myeloid leukemia in patients aged ≥50 years: young HLA-matched unrelated or haploidentical donor? , 2019, Haematologica.
[9] S. Devlin,et al. Racial disparities in access to HLA-matched unrelated donor transplants: a prospective 1312-patient analysis. , 2019, Blood advances.
[10] M. Konopleva,et al. Is a matched unrelated donor search needed for all allogeneic transplant candidates? , 2018, Blood advances.
[11] D. Blaise,et al. The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation , 2018, Bone Marrow Transplantation.
[12] Shannon R. McCurdy,et al. Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell-Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] G. Rosner,et al. Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide. , 2017, Blood advances.
[14] E. Shpall,et al. Post‐transplantation cyclophosphamide versus conventional graft‐versus‐host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation , 2016, British journal of haematology.
[15] M. Aljurf,et al. HLA Mismatch Is Associated with Worse Outcomes after Unrelated Donor Reduced-Intensity Conditioning Hematopoietic Cell Transplantation: An Analysis from the Center for International Blood and Marrow Transplant Research. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[16] R. Vij,et al. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. , 2015, Blood.
[17] M. MacMillan,et al. Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. , 2015, Blood.
[18] Medhat Askar,et al. Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation. , 2014, Blood.
[19] Loren Gragert,et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. , 2014, The New England journal of medicine.
[20] P. Westervelt,et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. , 2012, The New England journal of medicine.
[21] M. Horowitz,et al. Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia. , 2012, Blood.
[22] D. Porter,et al. Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. , 2011, Blood.
[23] J. Klein,et al. HLA-C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell transplantation. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[24] P. Hari,et al. Access to hematopoietic stem cell transplantation , 2010, Cancer.
[25] Allen R. Chen,et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[26] Harriet Noreen,et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. , 2007, Blood.
[27] Loren Gragert,et al. High-resolution HLA alleles and haplotypes in the United States population. , 2007, Human immunology.
[28] J. Klein,et al. IBMTR Severity INDEX FOR GRADING ACUTE GRAFT‐VERSUS‐HOST DISEASE: RETROSPECTIVE COMPARISON WITH GLUCKSBERG GRADE , 1997, British journal of haematology.
[29] M. Pasquini,et al. Current Use and Trends in Hematopoietic Cell Transplantation in the United States. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[30] M. Turner,et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.